Sutro Biopharma Participates in the 16th Annual World ADC Conference
Sutro Biopharma, Inc. (NASDAQ: STRO), an innovative company in oncology, has announced its involvement at the 16th Annual World ADC Conference. The event is taking place in San Diego and showcases a platform for exchanging insights in antibody-drug conjugate (ADC) development.
Showcasing Innovative Research
During the conference, Sutro is set to present groundbreaking preclinical data that highlight the company’s cutting-edge advancements and the pivotal progress they are making in revolutionizing ADC therapy. Hans-Peter Gerber, the Chief Scientific Officer of Sutro, expressed excitement about sharing results that underscore the transformational potential of their dual-payload ADCs, particularly in overcoming treatment challenges associated with oncology.
Enhancing Therapeutic Index
One of the critical focuses of Sutro’s research is on dual-payload ADCs that incorporate immunostimulatory capabilities. These innovations promise to enhance therapeutic indices and tackle tumor resistance, which remains a significant hurdle in cancer treatment today. Sutro's unique cell-free platform plays an integral role in developing these next-generation therapies.
Presentation Highlights
The conference features several key presentations by researchers from Sutro, with the promising advancements being a focal point:
- Site-Specific, High-DAR Dual-Payload ADCs Development
Presenter: Daniel Calerese, Ph.D.
Date/Time: November 3, 12:00 PM PT - Next-Generation Immunostimulatory ADCs
Presenter: Gang Yin, Ph.D.
Date/Time: November 3, 12:30 PM PT - Supply Chain Advantages in Cell-Free Manufacturing
Presenter: Venkatesh Srinivasan, Ph.D.
Date/Time: November 4, 11:00 AM PT - Panel Discussion on Novel ADC Design
Participant: Hans-Peter Gerber, Ph.D.
Date/Time: November 4, 5:00 PM PT - Overcoming Resistance Mechanisms
Presenter: Krishna Bajjuri, Ph.D.
Date/Time: November 5, 11:00 AM PT - Future Pathways for ADC Development
Participant: Daniel Calarese, Ph.D.
Date/Time: November 5, 12:30 PM PT - Discovery of STRO-006
Presenter: Alice Yam, Ph.D.
Date/Time: November 5, 2:00 PM PT - Promise in ADC Chemistry Innovation
Participant: Hans-Peter Gerber, Ph.D.
Date/Time: November 5, 3:00 PM PT
Post-Conference Resources
After the conference, attendees and interested parties can find the presentations in the Clinical/Scientific Presentation and Publication Highlights section on Sutro's official website.
About Sutro Biopharma
Sutro Biopharma specializes in advancing ADC technology aimed at delivering improved therapeutic outcomes for cancer patients. By leveraging a patented cell-free platform, the company creates ADCs that are designed to maximize drug delivery while minimizing side effects. Sutro is committed to targeting significant oncology markets with its innovative pipeline, which includes both single and dual-payload ADCs.
For further updates and insights, follow Sutro on social media @Sutrobio or visit www.sutrobio.com.
Frequently Asked Questions
What is the focus of Sutro Biopharma's presentations at the conference?
Sutro Biopharma will showcase preclinical data on their innovative dual-payload ADCs and other advancements in cancer treatment.
When is Sutro Biopharma presenting at the conference?
Sutro has several presentations scheduled between November 3 and November 5, 2025.
What are dual-payload ADCs?
Dual-payload ADCs are engineered to deliver two therapeutic agents targeting cancer cells, enhancing efficacy and overcoming resistance.
How does Sutro's cell-free platform contribute to its ADCs?
The cell-free platform enables precise control over the ADC creation process, enhancing drug exposure and reducing side effects.
Where can I find more information about Sutro Biopharma?
More details can be found on Sutro's official website or by following them on their social media channels.
